Anti-mPD1-MDNA213

N/A

Report date: 2025/02/14 11:13:13
First In Class

Base Information

Drug NameAnti-mPD1-MDNA213
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-PD-1Anti-IL13RA2
TargetsProgrammed cell death protein 1Interleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedicenna Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesMedicenna Therapeutics Corp
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A